본문으로 건너뛰기
← 뒤로

Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB.

2/5 보강
Cellular signalling 📖 저널 OA 7.2% 2023: 0/1 OA 2024: 1/14 OA 2025: 2/79 OA 2026: 10/85 OA 2023~2026 2026 Vol.143() p. 112490 OA S100 Proteins and Annexins
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-28
OpenAlex 토픽 · S100 Proteins and Annexins Cytokine Signaling Pathways and Interactions interferon and immune responses

Zhu L, Li G, Wang C, Bu L, Wu X, Chen X

📖 무료 전문 🔓 OA PDF oa
📝 환자 설명용 한 줄

Hepatocellular carcinoma (HCC) progression involves the synergistic roles of S100P and AURKB.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Lingyi Zhu, Guang Li, et al. (2026). Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB.. Cellular signalling, 143, 112490. https://doi.org/10.1016/j.cellsig.2026.112490
MLA Lingyi Zhu, et al.. "Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB.." Cellular signalling, vol. 143, 2026, pp. 112490.
PMID 41856224 ↗

Abstract

Hepatocellular carcinoma (HCC) progression involves the synergistic roles of S100P and AURKB. Using bioinformatics, molecular assays, and in vitro/vivo models, we show that S100P activates the RAGE/Ras/p-p38/NFκB pathway, upregulating MYBL2, which directly enhances AURKB transcription. Clinically, S100P correlates positively with AURKB expression and tumor immune suppression. HCC cells with low S100P expression showed significantly greater sensitivity to the AURKB inhibitor AZD1152-HQPA than control cells, with a 61% decrease in IC₅₀. This study reveals the S100P/MYBL2/AURKB axis as a key driver of HCC and a predictor of targeted therapy response, supporting precision treatment strategies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 1개

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기